These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 3278428)

  • 21. Monoclonal anti-T12 antibody as therapy for renal allograft rejection.
    Carpenter CB; Milford EL; Reinherz EL; Schlossman SF; Tilney NL; Strom TB; Kirkman RL; Busch GJ; Araujo JL
    Trans Assoc Am Physicians; 1983; 96():84-92. PubMed ID: 6388105
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monoclonal antibody (OKT3) rescue in refractory acute renal allograft rejection: report of 3 cases.
    Suvanapha R; Laorpatanaskul S; Vajaraphongse R; Kitisin P; Srivatanawongsa V; Mulikamas S; Vajaraphongse K; Boonvisut S; Chusil S; Panmuong W
    J Med Assoc Thai; 1989 Dec; 72(12):708-13. PubMed ID: 2628539
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Monoclonal antibody treatment of human allograft recipients.
    Delmonico FL; Cosimi AB
    Surg Gynecol Obstet; 1988 Jan; 166(1):89-98. PubMed ID: 3276014
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improved results using OKT3 as induction immunosuppression in renal allograft recipients with delayed graft function.
    Benvenisty AI; Cohen D; Stegall MD; Hardy MA
    Transplantation; 1990 Feb; 49(2):321-7. PubMed ID: 2137654
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized prospective trial of OKT3 for early prophylaxis of rejection after liver transplantation.
    Millis JM; McDiarmid SV; Hiatt JR; Brems JJ; Colonna JO; Klein AS; Ashizawa T; Hart J; Lewin K; Goldstein LI
    Transplantation; 1989 Jan; 47(1):82-8. PubMed ID: 2521409
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The use of OKT3 for stubborn heart allograft rejection: an advance in clinical immunotherapy?
    Sweeney MS; Sinnott JT; Cullison JP; Weinstein SS
    J Heart Transplant; 1987; 6(6):324-8. PubMed ID: 3320302
    [TBL] [Abstract][Full Text] [Related]  

  • 27. OKT3 treatment of steroid-resistant renal allograft rejection.
    Thistlethwaite JR; Gaber AO; Haag BW; Aronson AJ; Broelsch CE; Stuart JK; Stuart FP
    Transplantation; 1987 Feb; 43(2):176-84. PubMed ID: 3544373
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Increased infections associated with the use of OKT3 for treatment of steroid-resistant rejection in renal transplantation.
    Oh CS; Stratta RJ; Fox BC; Sollinger HW; Belzer FO; Maki DG
    Transplantation; 1988 Jan; 45(1):68-73. PubMed ID: 3276066
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Experience with OKT3 in vascularized pancreas transplantation.
    Sollinger HW; Stratta RJ
    Am J Kidney Dis; 1988 Feb; 11(2):145-8. PubMed ID: 3277405
    [TBL] [Abstract][Full Text] [Related]  

  • 30. FK 506 therapy for refractory renal allograft rejection: lessons from liver transplantation.
    Woodle ES; Bruce DS; Josephson M; Newell KA; Piper JB; Millis JM; Cronin D; Whitman G; Ruebe M; Thistlethwaite JR
    Clin Transplant; 1996 Aug; 10(4):323-32. PubMed ID: 8884103
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of a brief steroid trial before initiating OKT3 therapy for renal allograft rejection.
    Thistlethwaite JR; Stuart JK; Mayes JT; Gaber AO; Stuart FP
    Am J Kidney Dis; 1988 Feb; 11(2):94-8. PubMed ID: 3277413
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of anti-OKT3 antibody generation by cyclosporine--results of a prospective randomized trial.
    Hricik DE; Mayes JT; Schulak JA
    Transplantation; 1990 Aug; 50(2):237-40. PubMed ID: 2200174
    [TBL] [Abstract][Full Text] [Related]  

  • 33. OKT3-induced hypotension in heart allograft recipients treated for steroid-resistant rejection.
    Hosenpud JD; Norman DJ; Pantely GA; Cobanoglu AM; Starr A
    J Heart Transplant; 1989; 8(2):159-65; discussion 165-6. PubMed ID: 2651620
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A comparison of OKT3 monoclonal antibody and corticosteroids in the treatment of acute renal allograft rejection.
    Deierhoi MH; Barber WH; Curtis JJ; Julian BA; Luke RG; Hudson S; Barger BO; Diethelm AG
    Am J Kidney Dis; 1988 Feb; 11(2):86-9. PubMed ID: 3277412
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Influence of low-dose cyclosporine on the outcome of treatment with OKT3 for acute renal allograft rejection.
    Hricik DE; Zarconi J; Schulak JA
    Transplantation; 1989 Feb; 47(2):272-7. PubMed ID: 2493175
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Monoclonal antibody therapy. Anti-idiotypic and non-anti-idiotypic antibodies to OKT3 arising despite intense immunosuppression.
    Jaffers GJ; Fuller TC; Cosimi AB; Russell PS; Winn HJ; Colvin RB
    Transplantation; 1986 May; 41(5):572-8. PubMed ID: 3085297
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Infection in OKT3-treated patients receiving additional antirejection therapy.
    Munda R; Hutchins M; First MR; Carey M; Schroeder T; Alexander JW
    Transplant Proc; 1989 Feb; 21(1 Pt 2):1763-5. PubMed ID: 2652577
    [No Abstract]   [Full Text] [Related]  

  • 38. OKT3 treatment of cardiac allograft rejection.
    Haverty TP; Sanders M; Sheahan M
    J Heart Lung Transplant; 1993; 12(4):591-8. PubMed ID: 8369321
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Monoclonal antibodies in renal transplantation: a review.
    Parlevliet KJ; Schellekens PT
    Transpl Int; 1992 Sep; 5(4):234-46. PubMed ID: 1418316
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rejection episodes after liver transplantation during primary immunosuppression with FK506 or a cyclosporine-based regimen: a controlled, prospective, randomized trial.
    Jonas S; Kling N; Bechstein WO; Blumhardt G; Lohmann R; Lobeck H; Neuhaus P
    Clin Transplant; 1995 Oct; 9(5):406-14. PubMed ID: 8541635
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.